Eli Lilly said its experimental oral GLP-1 drug orforglipron outperformed Novo Nordisk’s oral semaglutide in a head-to-head phase 3 trial.
In a 52-week study involving 1,698 adults with Type 2 diabetes, the highest dose of orforglipron lowered average blood sugar by 2.2%, compared with 1.4% for the highest dose of oral semaglutide, according to a Sept. 17 news release from Eli Lilly.
The highest dose of Eli Lilly’s drug also resulted in patients losing an average of 9.2% of their weight, compared to 5.3% weight loss with Novo Nordisk’s pill.
Orforglipron has also shown clinical improvement across cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure and triglycerides, the release said.
Novo Nordisk, meanwhile, plans to seek FDA approval for its high-dose version of Wegovy, Bloomberg reported Sept. 16. Martin Holst Lange, MD, PhD, Novo Nordisk’s chief scientific officer, said high-dose Wegovy offers the same weight loss potential as Eli Lilly’s Zepbound.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
